Immune Design CS
(IMDZ)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2013 | 12-2012 | |
| Cash Flows From Operating Activities | ||
| Net Income | -15,975 | -10,840 |
| Depreciation Amortization | 407 | 548 |
| Accounts receivable | 426 | -452 |
| Accounts payable and accrued liabilities | -213 | 504 |
| Other Working Capital | -34 | 447 |
| Other Operating Activity | 1,091 | 215 |
| Operating Cash Flow | $-14,298 | $-9,578 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -132 | -294 |
| Investing Cash Flow | $-132 | $-294 |
| Cash Flows From Financing Activities | ||
| Common Stock Issued | 6 | 11 |
| Other Financing Activity | 32,049 | 10,615 |
| Financing Cash Flow | $32,055 | $10,626 |
| Beginning Cash Position | 12,762 | 12,008 |
| End Cash Position | 30,387 | 12,762 |
| Net Cash Flow | $17,625 | $754 |
| Free Cash Flow | ||
| Operating Cash Flow | -14,298 | -9,578 |
| Capital Expenditure | -175 | -294 |
| Free Cash Flow | -14,473 | -9,872 |